Dizal (Jiangsu) Pharmaceutical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Zhang Xiaolin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	1.8%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Zhang Xiaolin (60 yo)

no data

Permanencia

CN¥11,727,700

Compensación

Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhang Xiaolin	GM & Chairman	no data	CN¥11.73m	1.76% CN¥ 274.5m
Guanshan Zhu	Independent Director	4yrs	CN¥100.00k	sin datos
Simon Dazhong Lu	Director	7.7yrs	sin datos	sin datos
Rodolphe Peter Andre Grepinet	Director	7.7yrs	sin datos	sin datos
Jiang Bin	Independent Director	4yrs	CN¥100.00k	sin datos
Wang Xuegong	Independent Director	4yrs	CN¥100.00k	sin datos
Zhang Xin	Independent Director	4yrs	CN¥100.00k	sin datos
Dong Weiwen	Chairman of the Supervisory Board	no data	sin datos	sin datos
Yuan Sun	Supervisor	no data	sin datos	sin datos
Xiaojing Kang	Employee Supervisor	2.6yrs	sin datos	0.0041% CN¥ 638.2k

4.0yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de 688192 se considera experimentada (3.6 años de antigüedad promedio).

Dizal (Jiangsu) Pharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Less than half of directors are independent

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology